The Phase I trial of the company’s SRSD107 siRNA therapy found the treatment to be safe and well tolerated in its first-in-human tests.

The results from the Phase III trial found the LDL-C treatment to be well tolerated with a reduction in low-density lipoprotein cholesterol.

Vivoryon's VIVA-MIND trial echoed the disappointing AD findings of its VIVIAD trial but offers promise in treating kidney function.

AbbVie has reported that the Phase III TEMPO-2 trial of tavapadon for early-stage Parkinson's disease met its primary endpoint.

Enanta Pharmaceuticals has reported positive topline outcomes from a Phase II trial of zelicapavir for RSV in paediatric patients.

While treatments for chronic hand eczema are available, there is significant unmet need in long-term disease management and symptom control.

US-based pharmaceutical company MSD has published results from a Phase III trial of a potential combination therapy for ovarian cancer.

A panel highlighted the importance of supply chain prioritisation at the Outsourcing in Clinical Trials and Clinical Trial Supply East Asia conference in Seoul.

The US company has launched dosing in Taiwan for its Phase II trial of LP-300. In the US, some patients saw 51% tumour reduction.

BioAge Labs has halted the Phase II randomised STRIDES trial of azelaprag,following the observation of liver transaminitis in some patients.

GlobalData’s analysts predict $158 million in global sales for AZD0486 by 2030, with $2.4 billion for Epkinly and $949 million for Lunsumio.

Speaking at an Oncology conference in Munich, Suvoda’s Daniella Duffet detailed how long questionnaires can cost patients, time and data.